Analysts Expect Kiniksa Pharmaceuticals Ltd (KNSA) to Post -$0.74 EPS
Equities analysts expect Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) to post ($0.74) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kiniksa Pharmaceuticals’ earnings. The highest EPS estimate is ($0.62) and the lowest is ($0.85). The firm is expected to announce its next quarterly earnings report on Thursday, February 7th.
According to Zacks, analysts expect that Kiniksa Pharmaceuticals will report full year earnings of ($2.63) per share for the current year, with EPS estimates ranging from ($2.83) to ($2.42). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.08) per share, with EPS estimates ranging from ($3.42) to ($2.74). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Kiniksa Pharmaceuticals.
KNSA has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research report on Wednesday, November 7th. Wedbush reiterated an “outperform” rating and set a $33.00 price target (up previously from $31.00) on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, December 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Kiniksa Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $32.25.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its holdings in shares of Kiniksa Pharmaceuticals by 20.5% during the 4th quarter. Bank of New York Mellon Corp now owns 20,570 shares of the company’s stock valued at $578,000 after buying an additional 3,499 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Kiniksa Pharmaceuticals by 43.2% during the 4th quarter. BlackRock Inc. now owns 645,111 shares of the company’s stock valued at $18,120,000 after buying an additional 194,538 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at about $107,000. Virtus ETF Advisers LLC purchased a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter valued at about $380,000. Finally, Alps Advisors Inc. raised its holdings in shares of Kiniksa Pharmaceuticals by 30.7% during the 4th quarter. Alps Advisors Inc. now owns 36,453 shares of the company’s stock valued at $1,024,000 after buying an additional 8,560 shares in the last quarter. 37.93% of the stock is currently owned by institutional investors.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.
Featured Story: What is a short straddle?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.